KalVista Pharmaceuticals, Inc. (FRA:4XC1)

KalVista Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is May - April.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 28, 2025	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Market Capitalization	631	603	448	264	296	505
Market Cap Growth	27.44%	34.74%	69.56%	-10.92%	-41.24%	183.52%
Enterprise Value	608	474	384	116	120	464
Last Close Price	12.00	11.70	10.00	7.65	11.96	20.60
PS Ratio	505.98	-	-	-	-	-
PB Ratio	17.69	7.18	2.32	1.81	1.69	2.36
P/TBV Ratio	17.69	7.18	2.32	1.81	1.69	2.36
EV/FCF Ratio	-4.14	-	-	-	-	-
Debt / Equity Ratio	3.40	1.18	0.04	0.05	0.04	0.02
Asset Turnover	0.01	-	-	-	-	-
Quick Ratio	5.16	5.22	9.70	11.18	15.81	26.67
Current Ratio	5.37	5.35	9.90	11.46	16.73	27.04
Return on Equity (ROE)	-190.18%	-121.50%	-68.90%	-53.69%	-37.23%	-27.13%
Return on Assets (ROA)	-60.98%	-48.34%	-41.94%	-35.80%	-25.38%	-19.86%
Return on Capital (ROIC)	-70.75%	-55.75%	-45.82%	-38.23%	-26.46%	-20.78%
Return on Capital Employed (ROCE)	-114.50%	-91.40%	-66.10%	-65.90%	-50.20%	-22.10%
Earnings Yield	-28.15%	-26.80%	-26.45%	-31.88%	-26.35%	-7.62%
FCF Yield	-23.27%	-22.40%	-18.64%	-26.23%	-25.31%	-4.98%
Buyback Yield / Dilution	-29.51%	-34.98%	-31.89%	-13.96%	-28.17%	-7.58%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.